header logo image


Page 810«..1020..809810811812..820830..»

Genetics may be the reason why you hate vegetables, study shows – Yahoo Food

November 15th, 2019 8:46 pm

Cant stand the taste of vegetables? Your genes may be to blame.

Preliminary newresearchpresented at the American Heart Association (AHA) Scientific Sessions shows that a specific gene makes certain foods especially, broccoli, cauliflower, cabbage, and Brussels sprouts taste extremely bitter to some people.

The gene in question is calledTAS2R38. Everyone inherits two copies of this taste gene, but which variant of the gene you get makes all of the difference. According to the AHA: People who inherit two copies of the variant called AVI arent sensitive to bitter tastes from certain chemicals. Those with one copy of AVI and another called PAV perceive bitter tastes of these chemicals; however, individuals with two copies of PAV, often called super-tasters, find the same foods exceptionally bitter.

In the study, researchers analyzed questionnaires from 175 men and women about how often they ate certain foods and found that those with the PAV form of the gene who are more sensitive to bitter tasting foods were more than two and a half times as likely to eat the least amount of vegetables.

For super-tasters, the bitterness they taste in vegetables goes beyond being mildly annoying. A super-taster is a person who experiences a bitter taste with a much greater intensity than others,Tina Sindher, MD, an allergist and immunologist with Stanford Health Care, tells Yahoo Lifestyle, noting that super-tasters have many more visible taste papillae (bumps on the tongues surface) with more taste receptor cells compared to others.

Or as the lead author of the study,Jennifer L. Smith, PhD, RN, put it to theAHA: Were talking a ruin-your-day level of bitter when they tasted the test compound.

Super-tasters have the hardest time eating brassica vegetables broccoli, cauliflower, Brussels sprouts, cabbage, turnips, collards, kale, bok choy along with spinach, coffee, and tart citrus flavors. Studies show that bitter tasters eat fewer soy products and drink less green tea, and rated these foods to be more bitter than non-tasters, says Sindher.

That bitterness is getting in the way of super-tasters eating their vegetables, which may mean losing out on some health benefits. An overall healthy diet thats rich in vegetables and fruits may reduce the risk ofheart disease, including heart attack andstroke, according to theU.S. Department of Agriculture. Vegetables are also a good source ofdietary fiber, which helps reduce blood cholesterol levels and may lower risk of heart disease.

And in case you were wondering, just because you hate cilantro doesnt mean youre a super-taster. Disgust with that particular herb, which some find smells like soap, is a combination of two genetic variants (one of which is tied to sensing odors), according toNature. Cilantros aroma is created by several substances, which include fragments of fat molecules called aldehydes the same (or similar) aldehydes youll find in soap and lotions, according to aNew York Timesreport.

Super-tasters are individuals who are sensitive to specific bitter compounds, none of which are found in cilantro, explains Sindher. In fact, an aversion to cilantro occurs due to genetic variants associated with sensing smells and sensitivity to the aldehyde chemicals that give cilantro its distinctive flavor.

But for true super-tasters, how can they make sure to eat their vegetables? Unfortunately, theres no obvious way to disguise the bitter taste, explains Sindher. However, some strategies may be to sprinkle some sweetness to help mask bitter flavors, she says. Spices can help enhance flavor. Adding a little fat can also decrease bitterness.

Read more from Yahoo Lifestyle:

Follow us on Instagram, Facebook and Twitter for nonstop inspiration delivered fresh to your feed, every day.

Read the original here:
Genetics may be the reason why you hate vegetables, study shows - Yahoo Food

Read More...

Aversion to Broccoli May Have Genetic Roots – Scientific American

November 15th, 2019 8:46 pm

If you have heart disease, your doctor might tell you, eat more vegetables. A tactic that haslimited success.

Getting people to change their diets is actually pretty hard. These are lessons I would give over and over again. And I would think, Why is this so hard to do?

Jennifer L. Smith is a nurse researcher at the University of Kentucky who now has a preliminary answer about why change is so hard: it might depend on your genes. Specifically, whether or not youre genetically predisposed to perceive bitternessand therefore bitter veggies.

So broccoli is definitely one of them. They tend to be cruciferous vegetables, like broccoli, cauliflower, cabbage, brussels sprouts, asparagus."

If you ever took that test in science class where you put a piece of paper on your tongue to see if it tastes bitter, you might already know your bitter status.

Smith took saliva samples from 175 adults known to be at risk of cardiovascular disease. She then did a genetic test to determine whether they had a copy of a bitter-taste gene variant. She also had them fill in a questionnaire about their eating habits.

After controlling for factors like age, gender, income, and so on, Smith found that people with a copy of the bitter-sensitive gene variant were just 40 percent as likely to report eating a lot of veggies as were the folks without the gene variant.

Shes presenting the results this week at the American Heart Association Scientific Sessionsin Philadelphia. [Jennifer L. Smith et al., TAS2R38 haplotype predicts vegetable consumption in community dwelling adults at risk for cardiovascular disease]

If these findings hold up to more testing, Smith says, perhaps doctors could advise patients with this gene variant to avoid the most offensively bitter veggies but to try the others. Or perhaps certain herbs and spices might counteract the bitterness, she says.

Of course, chefs already figured this outwith cheesy broccoli. But for heart patients, the better flavor might not be a favor.

Christopher Intagliata

[The above text is a transcript of this podcast.]

Go here to see the original:
Aversion to Broccoli May Have Genetic Roots - Scientific American

Read More...

Endangered birds leave genetic clues in their drinking water – Cosmos

November 15th, 2019 8:46 pm

By Natalie Parletta

Australian researchers have worked out how to trace an endangered bird species by analysing water samples from its drinking holes.

Using environmental DNA (eDNA), a team led by Karen Gibb from Charles Darwin University identified the movements of the stunning rainbow-coloured Gouldian finch (Erythrura gouldiae), a species native to tropical savanna woodlands in Australias north.

Once numbering in the millions, there are now just 2500 adults as a result of the illegal bird trade, altered habitat, predators and wildfires, and the species is listed as endangered.

eDNA is used to detect the locations and numbers of rare and threatened species from water samples and to date has mostly been applied to freshwater animals.

Gibbs and team, including colleagues from the University of Western Australia, saw an opportunity to track the Gouldian finch using water sample analysis, as it needs to drink several times a day.

To do this, they developed a test that can identify estrildid finches from a fragment of mitochondrial DNA, and a probe specifically designed to detect Gouldian finch DNA.

This was necessary to distinguish the colourful finches from masked finches (Poephila personata) and long-tailed finches (P. acuticauda) other estrildid species that often flock together at the same waterholes.

Its a much more accurate test, says Gibb. By having primers that pick up other finches it tells us the eDNA is good enough quality to be amplified. If the Gouldian test is then negative, we can be confident that the eDNA test worked, but there just werent Gouldian finches at that site.

First, they piloted it in wildlife park aviaries before doing field trials at the Yinberrie Hills in the Northern Territory, where scientists and rangers had good observation data to validate the tests.

With a 200-millilitre water sample they could successfully detect Gouldian finch eDNA from waterholes the birds had visited in the previous 48 hours, and where there were lots of birds, it was still measurable from the samples two weeks later.

When it worked in the real world at the waterholes, even where the water was poor quality in places where it was hot and looked a bit oily we were really excited, says Gibb.

The study opens new options for rangers and scientists to keep track of the birds movements by simply collecting small water samples during their explorations, which will help inform conservation efforts.

People who are travelling around will be able to put a cup of water into an appropriate container and then into a car fridge, and be able to take a lot of samples, Gibbs says. We can cover a much larger area.

The study is published in the journal Endangered Species Research.

Read more:
Endangered birds leave genetic clues in their drinking water - Cosmos

Read More...

Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease…

November 15th, 2019 8:45 pm

--Study announced in conjunction with American Heart Association's Scientific Sessions--

--Researchers also presenting data on limitations of highly targeted screening strategies in familial hypercholesterolemia--

PHILADELPHIA, Nov. 15, 2019 /PRNewswire/ --Invitae Corporation (NVTA), a leading medical genetics company, today announced Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease. The first study on the platform will evaluate genetics in cardiovascular disease and was announced in conjunction with the American Heart Association's Scientific Sessions where researchers are presenting data on genetic screening in familial hypercholesterolemia.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. http://www.invitae.com (PRNewsFoto/Invitae Corporation)

"The creation of the Invitae Discover platform will make it easier to conduct studies that assess genetic test results alongside the biometric data that is now easily available on Apple Watch, thereby joining basic electrophysiological data with genetic information in order to advance our understanding of the genetic underpinnings of disease and help improve clinical care," said Robert Nussbaum, M.D., chief medical officer of Invitae. "Our first study on the platform is designed to determine the contribution of certain genetic variants to clinical presentations of atrial fibrillation and other cardiovascular conditions associated with abnormal heart rhythms, as well as to improve the interpretation of genetic testing results."

The first study on Invitae Discover is the Afib CAUSE Study. Patients who have genetic testing through Invitae can enroll in the study via the Invitae Discover app. The study will combine health and activity data from Apple HealthKit with clinical genetic testing results. In addition to assessing known genetic variants, the study will specifically evaluate biometric data for patients whose genetic testing included variants of uncertain significance (VUS) to help build preliminary data that improves variant classification and, ultimately, provide evidence to support resolution. The Invitae Discover app is available on the Apple app store. The Afib CAUSE study is open to U.S. residents 18 years of age and older and enrollment criteria can be accessed through the Invitae Discover app.

The study will be conducted under the supervision of an Institutional Review Board (IRB). As a medical genetics company, Invitae is subject to and fully complies with the privacy and security requirements under HIPAA for all its patients.

Separately at the AHA Scientific Sessions, Invitae researchers will be participating in a moderated poster session at the AHA meeting to discuss research quantifying the low diagnostic yield of highly targeted, direct-to-consumer genetic screening strategies in familial hypercholesterolemia. The study will be presented on November 17th during the Cardiovascular Genomic Medicine session at 2:20pm.

About InvitaeInvitae Corporation (NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website atinvitae.com.

Story continues

Safe Harbor StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and potential benefits of the company's clinical research platform; and the design and potential benefits of the company's first study on the platform. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Contact:Laura D'Angelo pr@invitae.com (628) 213-3283

View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-launches-invitae-discover-research-platform-on-apple-watch-first-study-on-platform-will-investigate-genetic-causes-of-cardiovascular-disease-300959136.html

Continue reading here:
Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease...

Read More...

Correlation Found Between Left-Handedness and Genetic Markers Associated with Neurological Disease – JD Supra

November 15th, 2019 8:45 pm

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

Read the original post:
Correlation Found Between Left-Handedness and Genetic Markers Associated with Neurological Disease - JD Supra

Read More...

Investigative Genetic Genealogy Used to Charge Man With Murder, Rape in 1980s SoCal Killings of 2 Women – KTLA Los Angeles

November 15th, 2019 8:45 pm

Please enable Javascript to watch this video

Prosecutors have charged a man with murder and rape in the killings of two women during the 1980s, after using investigative genetic genealogy to solve the crimes, Los Angeles County District Attorney Jackie Lacey said in a news release Friday.

The charges filed Friday are the first in L.A. County to use the forensic technology, authorities said.

Thanks to advances in technology and forensics, we are now able to virtually reach back in time and find those responsible for these vicious crimes, District Attorney Lacey said.

Horace Van Vaultz Jr., 64, was charged with two counts of murder, with special circumstance allegations of multiple murders, crimes committed during a rape and sodomy, and with lying in wait for each victim, the news release said.

Van Vaultz is accused of murdering Mary Duggan, 22, on June 9, 1986. Duggan's body was found in the trunk of a car in a Burbank parking lot, authorities said. She was bound, sexually assaulted and died from asphyxia because a tissue was stuffed down her throat, according to the release.

The second murder charge is for the killing of Selena Keough, 20, on July 16, 1981. Keough was found under some bushes in Montclair in San Bernardino County. She was also bound, sexually assaulted and strangled, authorities said.

Van Vaultz faces the death penalty or life in prison with the possibility of parole if convicted of the charges, the DA's office said.

His arraignment is expected to take place on Monday.

Investigators have reached out to other law enforcement agencies to determine if Van Vaultz is responsible for other unsolved murders in the state, the release said.

With dedicated resources and rapidly advancing technology, we can unmask the cowardly murderers who have remained hidden in our community and bring justice to the grief-stricken families who have waited too long for answers, Lacey said in the release.

The case remains under investigation by the Burbank and Montclair police departments and the FBI's Forensic Genetic Genealogy Team, authorities said.

Anyone with information is asked to contact the Burbank Police Department tip line at 818-238-3086.

34.052227-118.243660

Continued here:
Investigative Genetic Genealogy Used to Charge Man With Murder, Rape in 1980s SoCal Killings of 2 Women - KTLA Los Angeles

Read More...

Is sexual orientation genetic? Yes and no, an extensive study finds – Haaretz

November 15th, 2019 8:45 pm

The international group of scientists knew they were setting out to investigate an explosive subject: the hereditary basis of human same-sex behavior. Even so, the members of the prestigious Broad Institute in Cambridge, Massachusetts, may not have anticipated the magnitude of the public furor that erupted when they published their study, which identified several markers in certain genetic loci in the human genome related to same-sex sexual experience. The storm of reactions ranged from those who welcomed something seen as heralding significant progress in the field, to others who maintained that it would have been better if the scientists hadnt published anything.

The research results were published in full in the journal Science, at the end of August. This was the most extensive study of its kind ever conducted (there were about a half a million subjects), in which use was made of the GWAS (genome-wide association studies) method to analyze genetic big data. The researchers discovered five genetic markers (frequent, minor changes in the DNA segments of certain chromosomes) that appeared repeatedly among individuals who reported having had same-sex sexual experiences. Slight and frequent genetic variations were identified in both women and men, two others in men only and one more only in women.

No less important in the study, entitled Large-scale GWAS reveals insights into the genetic architecture of same-sex sexual behavior, is the scientists claim that a large number of genetic markers, perhaps even thousands, might operate simultaneously together although each in and of itself is of minuscule weight and influence ones same-sex orientation. Moreover, their study led the researchers to the conclusion that human genetics can explain up to 32 percent of same-sex sexual behavior.

What is at issue here, however, is not what the study contains but what it does not contain. As Melinda Mills, a sociology professor at Oxford, writes in the same issue of Science, there is no way that the researchers findings can be used as a tool to accurately predict same-sex behavior. Specifically, the fact that genetics can explain up to 32 percent of the fact that someone is gay or lesbian, does not mean that sexual identity is determined primarily by environmental factors not to mention social ones. This story is far more complex and has not yet been fully deciphered. Mills views are shared by Andrea Ganna, one of the chief authors of the new study.

What we basically do is statistical associations between having and not having these genetic markers and having or not having same-sex behavior, Ganna told Haaretz in a phone interview. Because we had this uniquely large study, he continued, which allowed us to have robust conclusions, and because we had the technology to measure the genetic markers of so many individuals, the time was right to confirm something that we expected: There is no one specific gay gene. Instead there are a lot of relatively common genetic markers, genetic mutations, that have a small effect on same-sex behavior.

At the same time, adds Ganna, a geneticist at Harvard Medical School and at Finlands Institute of Molecular Medicine, Not everyone is interpreting the fact that theres no single gay gene in the right way.

Gannas concern is shared by scientists around the world. Theyre worried that the researchers findings will fuel prejudice and discrimination against the LGBTQ community, and even spark calls for genetic engineering and genetic diagnosis among its members. So serious are these apprehensions that some have wondered whether the study would not do more harm than good.

As a queer person and a geneticist, I struggle to understand the motivations behind a genome-wide association study for non-heterosexual behavior, Joseph Vitti, a postdoctoral researcher at the Broad Institute, wrote on its blog, adding, I have yet to see a compelling argument that the potential benefits of this study outweigh its potential harms [T]he results presented not only oversimplify the question of biological causality, but also threaten direct damage by perpetuating the stereotype of LGBTQIA+ people as imprudent, while also likening same-sex attraction to a medical or psychological disorder.

Moreover, a website called The American Conservative posted an article entitled Not Born This Way After All? which wondered, skeptically: If the study proves that homosexuality is related to the environment, above all, and not to heredity why isnt it right and proper, in scientific terms, to allow those who so desire to undergo treatment in order to reduce their same-sex desires, which have now been shown not to be genetic?

That, however, is a simplistic reading of the studys findings. According to Michael Bailey, a professor of psychology at Northwestern University in Illinois, who was not involved in the study but has been conducting research on sexual orientation for 30 years, Its very important to understand that environment does not simply refer to social surroundings, like what your parents teach you and what kids you know, trauma and so on theres also a biological environment that begins right after conception.

Three years ago, Bailey and several colleagues published a survey of all the studies and professional literature in the field. The best studies have shown that genes are probably important but not overwhelmingly important, he tells Haaretz. We estimated in our 2016 review that 30 percent of the variation in sexual orientation is due to genetic variations. It may be this finding that led him to conclude that it is the biological environment that is mostly important. Bailey is convinced that men are born with their sexual orientation and that it is not subsequently acquired at any stage. He notes that there are several cases, I think there are seven throughout the professional literature, in which a baby boy was changed into a girl for medical reasons and was raised as a girl. When you follow these individuals through adulthood, you find that they are attracted to women and not to men.

In Baileys view, the best example of how biological-environmental factors can influence sexual orientation is the fraternal birth order effect. The phenomenon, whose existence is well established, he says, shows that the more older brothers a man has, the more likely he is to be homosexual. In practice, every older biological brother increases the probability that the youngest brother will be gay by about 33 percent. Thus, if the probability that a man with no older brothers will be gay is 2 percent, one older brother will increase the probability to 2.6 percent, and a second, third and fourth brother to 3.5 percent, 4.6 percent and 6 percent, respectively. Whats not yet clear is the reason for this.

In my mind, Bailey suggests, the best hypothesis as to why this happens is that a mothers immune system becomes increasingly active and produces antibodies against male proteins over successive births.

Fingers and hands

Behind this hypothesis is one of the most influential figures in the field, American-Canadian clinical psychologist and sexologist Ray Milton Blanchard. He was also among those who linked the fraternal birth order effect to another phenomenon of interest to scientists: the connection between being left-handed and having a same-sex orientation. The most extensive study in this regard was conducted in 2000, incorporating 20 different studies involving 7,000 gay male and female subjects and 16,000 heterosexual ones. It was found that gay men were 34 percent more likely to be left-handed. The situation was more extreme among lesbians: They were seen to have a 91 percent greater chance than straight women of writing with their left hand.

As a result, six years later, a research team led by Blanchard argued that the fraternal birth-order effect is relevant only among right-handed men. The reason is that, in any case, left-handed men who dont have older brothers already have a greater likelihood of being gay than right-handed men with such siblings.

A persons dominant hand turns out to be significant in another sense as well. An article published two years ago (about a study in which all the subjects had taken part in a gay pride parade in Toronto) found a connection between that hand and the gay persons role in bed: that is, the proportion of left-handed gays who defined their sexual behavior as passive or versatile (i.e., sometimes passive, sometimes not) was significantly higher than among those who described themselves as actives who clearly tended to be right-handed.

In research conducted over the years on the subject of the connection between sexual orientation and other attributes of the body, the hand holds a place of honor. But while Blanchard developed his theory on the basis of the whole hand, sometimes a few fingers are also enough: two, to be exact. In his 1998 study, British biologist John Manning confirmed a relatively old hypothesis, first put forward in Germany almost 150 years ago. Its gist is that the proportion between the length of index and ring fingers is, typically, different in men and women. Manning found that this phenomenon was detectable as early as age 2, which led to the observation that its source lies in the differences in testosterone and estrogen levels that already exist in the womb hereinafter: a biological-environmental factor.

Manning did not emphasize the element of sexual orientation in the two books and over 60 articles he wrote on this subject, but in the two decades that have elapsed since his study, more than 1,400 papers have been written on the ratio between the length of the second and fourth fingers (known as 2D:4D) and the connection between it and the level of risk of contracting certain diseases, as well as personality traits, cognitive and athletic abilities and sexual orientation.

One such study, published in 2010, maintained that straight and lesbian women are differentiated by the ratio between the length of the index and ring fingers, with lesbians tending to show a more masculine ratio i.e., closer to the average difference between the length of the fingers, among men. However, no such differences were found between gay and straight men.

Last year a team of scientists led by a British psychologist measured the fingers of 18 pairs of identical female twins, one lesbian, the other straight. Overall, differences in proportion were documented only in the lesbians and only in their left hand, and were comparable to the situation among men. This fact, the team concluded, could indicate a heightened exposure to testosterone in the womb but their study was based on a very small sample and drew much criticism. The critics charged that the conclusion was based on an overly simple means of measurement: of the way only two variables impacted each other. And, they added to bolster their argument, findings of studies involving those fingers have not been replicated in scientific experiments.

The field of gay science has been on a roll in recent years, but has a far longer history. Its modern phase dates to the early 1990s, when scientists began to publish increasing numbers of studies arguing that sexual orientation has a biological component. A leading scientist in this field is British-American neurobiologist Simon LeVay, who in 1990 performed autopsies on the bodies of 41 people: 19 gay men, 16 straight men and nine women. He discovered that the brain cells known as INAH-3 among the deceased gay men were relatively small, and closer in size to those of women than to heterosexual males.

In 1991, LeVay told Haaretz in a phone conversation, I published a study that got a lot of media attention, related to my observation that there was a region inside the hypothalamus that was different in size between men and women, and also between gay and straight men My additional finding was the difference in size between gay and straight men in this region inside the hypothalamus that is involved in the regulation of sexual behavior.

Adds LeVay, My general feeling is that there are certainly strong biological influences on peoples sexual orientation, but we cant say everything is genetic.

In the spirit of the period, and in light of the AIDS epidemic at the time, LeVay tried to be as cautious as possible about his conclusions. Its important to stress what I didnt find, he said in an interview to Discover magazine, in 1994. I did not prove that homosexuality is genetic, or find a genetic cause for being gay. I didnt show that gay men are born that way, [which is] the most common mistake people make in interpreting my work.

Three decades after publishing his study, he still thinks media coverage is doing an injustice to research even if its not his. Ive seen some headlines saying, basically, that this study [i.e., that of Ganna and his associates] shows its not genetic, or that are no gay genes, or something like that; and, of course, its not what the study shows at all.

Truly gay

In recent decades, scientific research (on men and women alike) in this realm has relied on an additional field: molecular genetics. The pioneer is geneticist Dean Hamer, who in 1993 conducted the first study of its kind.

We noticed that being gay, for males, tended to pass down through the mothers side of the family, he told Haaretz. And that is characteristic in genetics of something on the X chromosome because males get their X chromosomes from their moms That led us to look in families where there were gay brothers, to see if they shared anything on the X chromosome.

And thus, recalls Hamer, he and his team discovered Xq28: a genetic marker that plays a part in determining whether a person will be heterosexual or gay. He emphasizes that this is a factor, its not the factor and actually, overall, its not even the most important factor. He adds, Whats good about genetic studies, is that you know that whatever you find is a causal factor, because of course people are born with their genes, and its not something that changes over time.

LeVay, he explains, is looking directly at the brain, and were looking at what we think is building the brain and genes. Yet, its very difficult to know whether one was born with a brain like that, or whether that brain developed that way because of your behavior the causality is rather unknown.

At the same time, Hamer adds, That doesnt mean there arent specific pathways, because there has to be some sort of a pathway in the brain that controls sexual orientation. We know, for example, that the reason you become a male or a female is very simple: If you have a certain gene on the Y chromosome, you will produce male hormones, and if you have those you make a penis and scrotum and you become male. Accordingly, Theres probably some pathway in the brain that does same thing for sexual orientation, but were not going to discover it from genetics The answer will probably emerge from some sort of very sophisticated brain and developmental studies.

For 35 years, Hamer accumulated experience as a scientist at the National Institutes of Health in Bethesda, Maryland. That period is behind him. He doffed the white coat and now lives in Hawaii, where he makes films. But even if hes no longer occupied with research, it still occupies him.

Hamer: Back in the 1990s, I, along with all the scientists involved, believed that if we did good genetic studies wed find the important genes. For example, well find a gene that is responsible for the production of testosterone, and if its functioning was low, it would be possible to say that this is the cause of homosexuality in a particular person. But it turns out that it doesnt work that way. For every mental trait that has been studied everything you can imagine in the brain, for every single trait, theres a [vast number of] genes not to mention a host of complex societal and environmental factors.

For his part, Hamer has much praise for the Broad Institute study: The new GWAS study is really important, because for the very first time they used a huge sample and they mapped every inch of the genome. And this has never been done before. All the other studies were much smaller, or used many fewer genetic markers. But he also demurs: Whats very important is to look at what they actually analyzed. They didnt analyze people who were gay or lesbian, but anyone who had one single same-sex experience, which is quite different... They were measuring something more like openness to sexual experimentation.

As Hamer sees it, If you look for those five markers, or even just the three strongest markers, they are not necessarily found in people who actually identify as gay or lesbian. If you take people who are gay, like me, and look for those markers theyre not significantly there.

Hamer thinks that the whole field is lagging behind because of insufficient research, owing to the stigmas that plague the subject. I dont think sexuality is any more complicated than many other areas of human personality and individual differences, he observes, noting, We formally established that male sexuality is something that is deeply ingrained in people, its not any sort of choice really. It starts really early in life, and it has a major biological component to it. But, how it works? What the biological component is? Were completely unaware and dont know anything, and we barely know more than we did 25 years ago, or in the 1940s, when Kinsey did his work, to be honest.

Hamer was referring to biologist Alfred Kinsey, who in 1948 stunned the American public with his book, Sexual Behavior in the Human Male, which addressed previously taboo subjects, and challenged the traditional beliefs and existing knowledge about human sexuality. Kinsey had conducted a survey of men, which found that 37 percent of his subjects said they had undergone a homosexual experience of some kind, and 10 percent said they had been exclusively gay for three years of their adult life a statistic which to this day is generally said to represent the proportion of people engaging in same-sex behavior.

At the same time, subsequent studies reveal that the percentage of people who define themselves as exclusively homosexual is far lower, though it fluctuates from one article to the next. For example, a 2011 survey of nine different studies on the subject revealed that approximately 3.5 percent of Americans identify themselves as gays, lesbians or bisexuals. A poll involving 1,000 Jewish Israelis in 2012 found that 11.3 percent of the male respondents and 15.2 percent of the female ones said they felt an attraction to members of the same sex. However, only 8.2 percent of the men categorized themselves as gay or bisexual, while 4.8 percent of the women said they were lesbian or bisexual.

For his part, Ganna, of the Broad Institute, understands some of the criticism of his research. What we studied is not related directly to the biology, but to extended environmental factors related to it. Its not about our sample size once you have a lot of individuals, you can capture very small effects. But are these directly influencing same-sex behavior, or other things related to this topic? As a medical example, think about a study that looks for associations between genetic markers and lung cancer. In that example, what we found are genetic variants regarding how much you smoke, which is related to lung cancer.

One of the lessons, and one of the most interesting points arising from the study has to do, says Ganna, with the mode of measurement that had been in use since 1948, when Kinseys scale ranked individuals as being between 0 (totally heterosexual) and 6 (totally homosexual).

Ganna: Basically, the tendency is to locate individuals on a continuum. You can supposedly be anywhere between 100 percent heterosexual to 100 percent homosexual, which implies that the more youre homosexual, the less youre heterosexual, and vice versa. We show that this assumption actually doesnt hold water: When we look at the genetic data, its not that straightforward, theres no simple continuum of sexuality.

So, actually, you are refuting the Kinsey scale?

Ganna: Thats exactly one of our conclusions. What were now doing is, rather than asking people to put themselves on a scale somewhere between being exclusively heterosexual or exclusively homosexual, we ask them how much theyre attracted to men and women. You could be attracted to either of them, very attracted to both of them or to one more than the other. And that information will be crossmatched with genetic markers.

In the final analysis, he adds, We showed that this is just another natural human variation. Sexual orientation, similar to many other behavioral traits, is complicated and is composed of different factors. The interesting thing is how genetics and environment work together. If you think about how much more prevalent same-sex behavior has become lately, people engage in it more than in the past. And thats clearly not because our genetics are changing. Its because of the environment, because society is becoming more open and laws are changing.

Further research should focus on the relationship between environmental factors and genetics, Ganna says, and on how they interact. Its somewhat misleading to think of nature and nurture as separate aspects; they both contribute. So, it would be wrong to say that you can use only DNA to predict if someone will engage in same-sex behavior, but you also cant say its simply a [matter of] choice.

In summary, he says, I think that the more people who will understand that there are genetic and environmental components to sexual behavior, the better and this is a message that goes beyond just sexuality.

Choice and lifestyle

However, the relationship between science and the environment, and particularly the people living in it, is a complicated one. The subject definitely should be studied, but the social aspect of it is problematic, says LeVay, the neurobiologist. I am gay myself, and I feel strongly that gay people should be valued and accepted into society, regardless of what caused their sexual orientation. I dont think its vital for gay liberation to prove that gay people cant help but be gay there are plenty of other reasons [for accepting them], including basic human rights.

At the same time, he adds, this issue is socially relevant, because of traditional notions that see same-sex relations as a choice, a lifestyle or sinful behavior.

In recent years, there have been many studies showing that peoples attitudes toward homosexuality are closely tied to their beliefs about what makes people gay, says LeVay, citing a survey that showed there was a high probability that people who think homosexuality is a choice will object to a gay person being their childrens teacher which in a way might make sense, he adds: If you think being gay is something infectious, socially contagious, and you didnt want your kid to be gay, then you wouldnt want their teacher to be gay ... It follows that demonstrating that biological factors are involved, helps counter those ideas. Still, Im a bit ambivalent about the use of this type of research as some sort of a political weapon in the struggle for gay rights.

The Broad Institute study contains a reminder of the problems and stigmas that still exist with regard to the LGBTQ community. One of the parameters it considers are genetic correlations between genes that are ascribed to homosexuality, and certain psychological problems.

Bailey, the psychologist: One thing that was perceived as controversial, was to look for and find a genetic overlap between homosexual sex genes and genes associated with depression. Its not the same as saying all people who engage in homosexual sex are depressed for genetic reasons, but its also not something that can be easily ignored. There are assumptions that the higher rates of depression among gay men and lesbians is due to the way they are mistreated by society, but the evidence for that is not so overwhelming. There is also the fact, for example, that you have as high a rate of depression among homosexual men in the Netherlands, which is very tolerant, as you have in some less tolerant places, like the United States.

Ganna, for his part, tries to soften that criticism: Even if we see genetic overlap, or correlation, it is not set in stone that weve found a biological mechanism that causes depression and same-sex behavior, he says. There are many explanations for why this one genetic marker is associated with both things. But finding these correlations help us study human traits in general.

In the meantime, there is a price to be paid for conducting research in this realm, which all those involved must be aware of. Reminders of this abound, and are almost routine. In some cases whats at stake is not even a groundbreaking study or one of tremendous scientific importance. In 2017, for example, two researchers from Stanford published an article stating that gay men are predicted to have smaller jaws and chins, slimmer eyebrows, longer noses, and larger foreheads; the opposite should be true for lesbians. In the next stage, they created a facial-recognition program with the aid of more than 14,000 images taken from a singles site of straights and LGBTQs. The program was able to distinguish between gays and lesbians and heterosexuals with an accuracy of 81 percent for men and 71 percent for women, in contrast to an average rate of successful human guesses of 61 percent and 54 percent, respectively. Even though the program achieved relatively impressive results, the study as such drew widespread criticism not unusual for researchers engaged in such studies.

The Stanford gays identification program may be an extreme example, in this respect, but its also a byproduct of the considerable surge in studies in this field, a trend that began in the early 1990s. Together with the scientific community, media interest in the subject of same-sex orientation and its causes has contributed substantially to transmitting messages and shaping public opinion.

In the United States, this can be seen in a series of polls conducted by Gallup, Inc. The first one, conducted in 1977, found that only 13 percent of the respondents believed that homosexuality is an innate tendency, while 56 percent attributed it to environmental factors. This approach remained largely constant until the period between 1989 and 1996, when the rate of those supporting the innate thesis leaped from 19 percent to 31 percent; by 2001, it stood at 40 percent. Almost a decade and a half later, the annual poll produced, for the first time, a larger proportion who agreed with the innate argument. The latest survey, from the end of last year, showed this trend continuing: More than half of the American public believes that gay people are born with their sexual orientation, whereas only 30 percent attribute it to environmental factors (10 percent said both factors play a part, 4 percent cited other factors and 6 percent said they werent sure).

Changes in the perceptions of the origins of sexual orientation are having a pronounced effect on the struggle LGBTQ individuals are waging for equal rights. The latest Gallup poll shows that an absolutely majority (88 percent) of those who believe that homosexuality is an innate trait also support legitimizing same-sex marriages. In contrast, most of those who see this orientation as being environmentally driven (61 percent) are against.

When it comes to public opinion, which is very important, the born this way idea has been really resonant and has had a very positive impact on society, Hamer maintains. Public opinion polls asked people whether they think [gays] were born this way or not, and we know that believing that homosexuality is innate correlates with having positive feelings toward gay rights. Overall, its been important in educating the public about who we are, as gay people.

Such messages are reaching Israel as well. A poll conducted by the Dialog Institute for Haaretz at the end of 2013 found that 70 percent of those questioned favored full rights for same-sex couples, while 64 percent specifically backed their right to surrogacy. However, two polls conducted in the wake of the surrogacy law protest in July 2018 presented slightly lower numbers: About 57 percent of respondents expressed support for the right of same-sex male couples to surrogacy.

These polls did not ask Israelis whether they believe the origin of same-sex orientation is innate or environmental. If you ask Bailey, though, that doesnt really matter.

Ive gone to great lengths to try to persuade people not to base equal rights for gay people on the causal hypothesis, he says. Its a terrible idea to say gay people should have equal rights because they were born that way. Its terrible in part because some criminals might be born that way, and you dont want to them to have the same rights. Being gay doesnt harm anybody, other than people who are close-minded and easily offended. Preventing people from expressing their homosexuality is quite destructive for them. Thats true whether gay people are born that way or not.

Read more here:
Is sexual orientation genetic? Yes and no, an extensive study finds - Haaretz

Read More...

Bayer and Dewpoint Therapeutics Ink $100 Million Research Partnership – BioSpace

November 15th, 2019 8:45 pm

Germany-based Bayer and Dewpoint Therapeutics, located in Boston, announced a research deal that could hit $100 million. The research pact will leverage Dewpoints biomolecular condensates technology platform and Bayers small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.

Biomolecular condensates are droplet-like membrane-less organelles that form in a dynamic fashion with many proteins in order to function within cells. About 80% of proteins in humans are considered unreachable with small molecule drugs. The companies believe that with Dewpoints platform, they will broaden the reach of small molecule therapeutics, identifying new drug targets.

As we continue to broaden our capabilities in Research & Development, the collaboration with Dewpoint gives us access to breakthrough innovation potential, said Joerg Moeller, member of Bayers executive committees Pharmaceuticals Division and head of Research and Development. New analytic tools and a growing understanding of biomolecular condensates could provide new insights into cellular functions that previously have not been considered by scientists in drug development, enabling us to identify novel pharmacological targets for future therapies.

Under the terms of the deal, Bayer picks up an option to exclusively license a specific number of novel therapeutics that come out of the research. In addition to access to Bayers small molecule compound library, it brings R&D capabilities including high throughput screening and medicinal chemistry. No other financial details were disclosed. Nor was the length of the pact.

In January 2019, Bayer participated in Dewpoints $60 million Series A financing via the Leaps by Bayer investment unit.

Dewpoint has locations in Boston and Dresden, Germany. Part of the agreement is to expand Dewpoints presence in Germany outside of Dresden.

This partnership is an exciting opportunity to advance treatments for diseases that have long evaded the industry, said Amir Nashat, Dewpoints chief executive officer. We look forward to combining Bayers expertise in chemistry and drug development and Dewpoints novel platform and insights into the role of biomolecular condensates in disease. We also look forward to working closely with Bayer to expand our capabilities in Germany and put the local biotech ecosystem at the forefront of this important and emerging area.

Dewpoint was founded by Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and Richard Young of the Whitehead Institute in Cambridge, Massachusetts. At the Series A, additional investors besides Bayer included founding investor Polaris Partners, Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, and Alexandria Venture Investments.

Although the research partnership between Dewpoint and Bayer will focus on cardiovascular and gynecologic diseases, numerous other diseases are affected by condensates including cancer, neurodegenerative disorders, immunology and virology.

At the time of the launch, Hyman said, Insights into biomolecular condensates could provide answers to fundamental mysteries in biology, and we are eager to begin using these to discover new therapeutic approaches to diseases.

The companys scientific advisors include Simon Alberti, professor and chair of Cellular Biochemistry at the Technical University Dresden; Arup Chakraborty, Robert T. Haslam Professor of Chemical Engineering and Professor of Physics and Chemistry at MIT; Bradley Hyman, John B. Penny, Jr. Professor of Neurology at Harvard Medical School and Director of the Alzheimers unit at Mass General Institute for Neurological Disease; Rudolf Jaenisch, Whitehead Institute Founding Member and Professor of Biology at MIT; Robert Langer, David H. Koch Institute Professor at MIT; Timothy Mitchison, Hasib Sabbagh Professor of Systems Biology at Harvard Medical School and Director of the Harvard Therapeutics Innovation Hub; and Rohit Pappu, Edwin H. Murty Professor of Engineering in the Department of Biomedical Engineering and Director of the Center for the Science & Engineering of Living Systems at Washington University in St. Louis.

View post:
Bayer and Dewpoint Therapeutics Ink $100 Million Research Partnership - BioSpace

Read More...

Mapping human antibodies to develop protein therapeutics spotlighted at Feinstein Institutes Marsh Lecture – BioSpace

November 15th, 2019 8:45 pm

MANHASSET, N.Y., Nov. 15, 2019 /PRNewswire/ --The Feinstein Institutes for Medical Researchhosted a Marsh Lecture given by George Georgiou, PhD, of the University of Texas at Austin, to discuss human antibody repertoire and the development of protein therapeutics to help treat cancer, viral infection and autoimmune disorders.

Dr. Georgiou, the Laura Jennings-Turner Chair Professor in the departments of Chemical Engineering and Molecular Biosciences at Texas, researches and develops methods to observe and analyze, at the molecular-level, human antibody immune responses which ultimately leads to more efficient vaccines and other engineered enzyme therapeutics.

"To create more effective antibodies and vaccines for some of the most complicated medical conditions, we must better understand the body's molecular immune system," said Dr. Georgiou at the lecture on November 14.

TheMarsh Lectureis given by visiting prominent scientists who share their expertise and establish collaborations with Feinstein Institutes investigators. In his lecture, Dr. Georgiou emphasized the need to continue work in the discovery and preclinical development of protein therapeutics, the mapping of serological antibody repertoire in human health, disease and the methods to engineer second generation antibodies.

The lecture was co-hosted by the Feinstein Institutes' president and CEO, Kevin J. Tracey, MD,and the director of the Institute of Molecular Medicine, Betty Diamond, MD.

"Dr. Georgiou is a leader in defining how to exploit fundamental molecules of the immune system to make new therapies for patients with cancer and other disabling conditions," said Dr. Tracey.

The Feinstein Institutes' Marsh Lecture was established as a forum for renowned scientists to share their expertise with Feinstein Institutes investigators. The series was made possible by an endowment from the late Leonard Marsh and his family, the Marsh Lecture honors the memory of Leonard Marsh, co-founder of Snapple Beverage Corporation and a major supporter of the Feinstein Institutes. Leonard Marsh's legendaryenthusiasm for new ideas and innovations continue to inspire the Feinstein Institutes scientific faculty and staff.

For more information on this and upcoming Marsh Lectures,click here.

About the Feinstein Institutes The Feinstein Institutes for Medical Researchis the research arm of Northwell Health, the largest health care provider and private employer in New York. Home to 50 research labs, 2,500 clinical research studies and 4,000 researchers and staff, the Feinstein Institutes is raising the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We're making breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine a new field of science that has the potential to revolutionize medicine. For more information about how we're producing knowledge to cure disease, visit feinstein.northwell.edu.

Contact: Matthew Libassi516-465-8325mlibassi@northwell.edu

View original content to download multimedia:http://www.prnewswire.com/news-releases/mapping-human-antibodies-to-develop-protein-therapeutics-spotlighted-at-feinstein-institutes-marsh-lecture-300959137.html

SOURCE The Feinstein Institutes for Medical Research

Read more here:
Mapping human antibodies to develop protein therapeutics spotlighted at Feinstein Institutes Marsh Lecture - BioSpace

Read More...

Here’s a better way to convert dog years to human years, scientists say – Science Magazine

November 15th, 2019 8:45 pm

A biological clock governs aging in dogs just as in humans.

By Virginia MorellNov. 15, 2019 , 3:42 PM

Our Scotch collie, Buckaroo, is just shy of 14 years old. Following the long-debunked but still popular idea that one dog year equals seven human years, hes almost a centenarian. (This formula may be based on average life spans of 10 and 70 years for dogs and people, respectively.) Now, researchers say they have a new formula (see calculator below)to convert dog years to human yearsone with some actual science behind it.

The work is based on a relatively new concept in aging research: that chemical modifications to a persons DNA over a lifetime create what is known as an epigenetic clock. Scientists have built a case that one such modification, the addition of methyl groups to specific DNA sequences, tracks human biological agethat is, the toll that disease, poor lifestyle, and genetics take on our bodies. As a result, some groups have converted a persons DNA methylation status to an age estimateor even a prediction of life expectancy (worrying ethicists, who say the data could be misused by forensic investigators and insurance companies).

Other species also undergo DNA methylation as they age. Mice, chimpanzees, wolves, and dogs, for example, all seem to have epigenetic clocks. To find out how those clocks differ from the human version, geneticist Trey Ideker of the University of California, San Diego, and colleagues started with dogs. Even though mans best friends diverged from humans early in mammalian evolution, theyre a good group for comparison because they live in the same environments and many receive similar healthcare and hospital treatments.

All dogsno matter the breedfollow a similar developmental trajectory, reaching puberty around 10 months and dying before age 20. But to increase their chances of finding genetic factors associated with aging, Idekers team focused on a single breed: Labrador retrievers.

They scanned DNA methylation patterns in the genomes of 104 dogs, ranging from 4 weeks to 16 years of age. Their analysis revealed that dogs (at least Labrador retrievers) and humans do have similar age-related methylation of certain genomic regions with high mutation rates; those similarities were most apparent when the scientists looked at young dogs and young humans or old dogs and old humans. Most importantly, they found that certain groups of genes involved in development are similarly methylated during aging in both species. That suggests at least some aspects of aging are a continuation of development rather than a distinct processand that at least some of these changes are evolutionarily conserved in mammals, Ideker and colleagues report in a preprint posted online at bioRxiv.

We already knew that dogs get the same diseases and functional declines of aging that humans do, and this work provides evidence that similar molecular changes are also occurring during aging, says Matt Kaeberlein, a biogerontologist at the University of Washington in Seattle, who was not involved with this research. Its a beautiful demonstration of the conserved features of the epigenetic age clocks shared by dogs and humans.

The research team also used the rate of the methylation changes in dogs to match it to the human epigenetic clock, although the resulting dog age conversion is a bit more complex than multiply by seven. The new formula says a canines human age = 16 ln(dog age) + 31. (Thats the natural logarithm of the dogs real age, multiplied by 16, with 31 added to the total.)

Calculate

(*Enter numbers whose value is 1 or greater)

If your dog were a human, it would be:

Using that formula, dogs and humans life stages seem to match up. For example, a 7-week-old puppy would be equivalent to a 9-month-old human baby, both of whom are just starting to sprout teeth. The formula also nicely matches up the average life span of Labrador retrievers (12 years) with the worldwide lifetime expectancy of humans (70 years).

Theyve shown that theres a gradual increase in DNA methylation in both species with age, says Steve Austad, an evolutionary biologist and aging expert at the University of Alabama in Birmingham. He doesnt find that especially surprising, but he thinks the technique could reveal far more interesting results if applied to issues like the different life spans among different dog breeds.

Thats one goal of Kaeberlein, whose groups new Dog Aging Project (open to all breeds) will include epigenetic profiles of its canine subjects. He hopes to find out why some dogs develop disease at younger ages or die earlier than normal, whereas others live long, disease-free lives.

So, how does our Buckaroo fare? Happily, the epigenetic clock calculation goes in his favor. Hes now only 73 in human yearsand a spry 73 at that.

Read more:
Here's a better way to convert dog years to human years, scientists say - Science Magazine

Read More...

How maternal Zika infection results in newborn microcephaly – Baylor College of Medicine News

November 15th, 2019 8:45 pm

The current study was initiated when a patient presented with a small brain size at birth and severe abnormalities in brain structures at the Baylor Hopkins Center for Mendelian Genomics (CMG), a center directed by Dr. Jim Lupski, professor of pediatrics, molecular and human genetics at Baylor College of Medicine and attending physician at Texas Childrens Hospital, said Dr. Hugo J. Bellen, professor at Baylor, investigator at the Howard Hughes Medical Institute and Jan and Dan Duncan Neurological Research Institute at Texas Childrens Hospital.

This patient and others in a cohort at CMG had not been infected by Zika virus in utero. They had a genetic defect that caused microcephaly. CMG scientists determined that the ANKLE2 gene was associated with the condition. Interestingly, a few years back the Bellen lab had discovered in the fruit fly model that ANKLE2 gene was associated with neurodevelopmental disorders. Knowing that Zika virus infection in utero can cause microcephaly in newborns, the team explored the possibility that Zika virus was mediating its effects in the brain via ANKLE2.

In a subsequent fruit fly study, the researchers demonstrated that overexpression of Zika protein NS4A causes microcephaly in the flies by inhibiting the function of ANKLE2, a cell cycle regulator that acts by suppressing the activity of VRK1 protein.

Since very little is known about the role of ANKLE2 or VRK1 in brain development, Bellen and his colleagues applied a multidisciplinary approach to tease apart the exact mechanism underlying ANKLE2-associated microcephaly.

The team found that fruit fly larvae with mutations in ANKLE2 gene had small brains with dramatically fewer neuroblasts brain cell precursors and could not survive into adulthood. Experimental expression of the normal human version of ANKLE2 gene in mutant larvae restored all the defects, establishing the loss of Ankle2 function as the underlying cause.

To understand why ANKLE2 mutants have fewer neuroblasts and significantly smaller brains, we probed deeper into asymmetric cell divisions, a fundamental process that produces and maintains neuroblasts, also called neural stem cells, in the developing brains of flies and humans, said first author Dr. Nichole Link, postdoctoral associate in the Bellen lab.

Asymmetric cell division is an exquisitely regulated process by which neuroblasts produce two different cell types. One is a copy of the neuroblast and the other is a cell programmed to become a different type of cell, such as a neuron or glia.

Proper asymmetric distribution and division of these cells is crucial to normal brain development, as they need to generate a correct number of neurons, produce diverse neuronal lineages and replenish the pool of neuroblasts for further rounds of division.

When flies had reduced levels of Ankle2, key proteins, such as Par complex proteins and Miranda, were misplaced in the neuroblasts of Ankle2 larvae. Moreover, live imaging analysis of these neuroblasts showed many obvious signs of defective or incomplete cell divisions. These observations indicated that Ankle2 is a critical regulator of asymmetric cell divisions, said Link.

Further analyses revealed more details about how Ankle2 regulates asymmetric neuroblast division. They found that Ankle2 protein interacts with VRK1 kinases, and that Ankle2 mutants alter this interaction in ways that disrupt asymmetric cell division.

Linking our findings to Zika virusassociated microcephaly, we found that expressing Zika virus protein NS4A in flies caused microcephaly by hijacking the Ankle2/VRK1 regulation of asymmetric neuroblast divisions. This offers an explanation to why the severe microcephaly observed in patients with defects in the ANKLE2 and VRK1 genes is strikingly similar to that of infants with in utero Zika virus infection, Link said.

For decades, researchers have been unsuccessful in finding experimental evidence between defects in asymmetric cell divisions and microcephaly in vertebrate models. The current work makes a giant leap in that direction and provides strong evidence that links a single evolutionarily conserved Ankle2/VRK1 pathway as a regulator of asymmetric division of neuroblasts and microcephaly, Bellen said. Moreover, it shows that irrespective of the nature of the initial triggering event, whether it is a Zika virus infection or congenital mutations, the microcephaly converges on the disruption of Ankle2 and VRK1, making them promising drug targets.

Another important takeaway from this work is that studying a rare disorder (which refers to those resulting from rare disease-causing variations in ANKLE2 or VRK1 genes) originally observed in a single patient can lead to valuable mechanistic insights and open up exciting therapeutic possibilities to solve common human genetic disorders and viral infections.

Others who contributed in this study are Hyunglok Chung, Angad Jolly, Marjorie Withers, Burak Tepe, Benjamin R. Arenkiel, Priya S. Shah, Nevan J. Krogan, Hatip Aydin, Bilgen B. Geckinli, Tulay Tos, Sedat Isikay, Beyhan Tuysuz, Ganesh H. Mochida, Ajay X. Thomas, Robin D. Clark and Ghayda M. Mirzaa. They are affiliated to one or more of the institutions: Baylor College of Medicine, Texas Childrens Hospital and the Jan and Dan Duncan Neurological Research Institute in Houston, TX; University of California at Davis and San Francisco; Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Dr. Sami Ulus Research and Training Hospital of Women's and Children's Health and Diseases, Ankara, Turkey; Boston Childrens Hospital; Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA; Loma Linda University Medical Center, Loma Linda, CA; University of Washington, Seattle, WA; and Seattle Children's Research Institute, Seattle, WA.

The study was funded by the National Institutes of Healths F32NS092270, NIH/NINDS R35NS105078, NIH U54NS093793, NIH R24OD022005, NIH/NINDS K08NS092898, Howard Hughes Medical Institute (HHMI), Medical Research Fellowship, Jordans Guardian Angels, a jointly funded NHGRI and NHLBI grant to the Baylor-Hopkins Center for Mendelian Genomics (UM1 HG006542) and the Huffington Foundation.

Go here to read the rest:
How maternal Zika infection results in newborn microcephaly - Baylor College of Medicine News

Read More...

Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv,…

November 15th, 2019 8:44 pm

NESS ZIONA, Israel, Nov. 11, 2019 /PRNewswire/ --Kadimastem Ltd.(TASE: KDST),a clinical stage cell therapy company, today announced that it will present the interim results of Cohort A of its ongoing Phase 1/2a Clinical Trial in ALS (as published in Company's press release) at the 7th International Stem Cell Meeting, to be held on November 12-13 at the Dan Panorama Hotel in Tel Aviv, Israel.

The International Stem Cell Meeting, hosted by the Israel Stem Cell Society, is a highly reputed conference, participated by international world leaders in stem cell research.

Presentation Details:

Title: "FIRST IN HUMAN CLINICAL TRIALS WITH HUMAN ASTROCYTES AS A NOVEL CELL THERAPY FOR THE TREATMENT OF ALS"

Session:ONGOING CLINICAL TRIALS WITH CELL THERAPY

Presenter:Arik Hasson, PhD, Executive VP, Research and Development, Kadimastem

Date:Wednesday, November 13, 2019

Time:1:50 pm Israel

Location: Dan Panorama Hotel, Tel Aviv, Israel

Rami Epstein, CEO of Kadimastem, stated: "We are pleased to share these results with global leaders in the cell therapy and stem cells industry,demonstrating the potential of AstroRx, our astrocyte-based cell therapy product,to bring treatment to ALS patients, and possibly other neurodegenerative diseases. We look forward to further share data of this ongoing trial, with final results of cohort A expected by year-end 2019and results of cohort B expected in Q3, 2020."

About the Phase 1/2a ALS Clinical Trial

The Phase 1/2a trial is an open label, dose escalating clinical study to evaluate the safety, tolerability and preliminary efficacy of AstroRxcells in patients with ALS. The trial is expected to include 21 patients and is being conducted at the Hadassah Medical Center, Jerusalem, Israel. The primary endpoints of the trial are safety evaluation and tolerability of a single administration of allogeneic astrocytes derived from human Embryonic Stem Cells (hESC), administered in escalating low, medium and high doses (100x106, 250x106, and 500x106 cells, respectively). The medium dose will also be administered in 2 consecutive injections separated by an interval of ~60 days. Secondary end points include efficacy evaluation and measurements. Treatment is administered in addition to the appropriate standard-of-care.

About AstroRx

AstroRx is a clinical grade cell therapy product developed and manufactured by Kadimastem in its GMP-compliant facility, containing functional healthy astrocytes (nervous system support cells) derived from human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons through several mechanisms of action. The Company's technology enables the injection of AstroRxcells into the spinal cord fluid of patients suffering from Amyotrophic Lateral Sclerosis (ALS) with the goal of supporting the malfunctioning cells in the brain and spinal cord, in order to slow the progression of the disease and improve patients' quality of life and life expectancy. AstroRxhas been shown to be safe and effective in preclinical studies. AstroRxhas been granted orphan drug designation by the FDA.

About ALS

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease causing disfunction in the upper and lower motor nerves that control muscle function. ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is 2-5 years. According to the ALS Therapy Development Institute, it is estimated that there are approximately 450,000 ALS patients worldwide of which 30,000 reside in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to US$ 6 Billion.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic proprietary cell products based on its platform technology for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells. AstroRx, the Company's lead program, is a clinical-grade astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. In addition, preclinical trials are ongoing with the Company's IsletRx pancreatic functional islet cells for the treatment of insulin dependent diabetes. Kadimastem was founded by Prof. Michel Revel, CSO of the Companyand Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Prof. Revel received the Israel Prize for the invention and development of Rebif, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Company Contacts:Yossi Nizhar, CFO y.nizhar@kadimastem.com+972-73-797-1613

Investor and Media Contact:Meirav Gomeh-Bauermeirav@bauerg.com+972-54-476-4979

Global Media Contact:Dasy (Hadas) MandelDirector of Business Development, Kadimastemd.mandel@kadimastem.com+972-73-797-1613

SOURCE Kadimastem

https://www.kadimastem.com/

Read more:
Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv,...

Read More...

More Ways of Information Sharing Found in Living Things – Discovery Institute

November 15th, 2019 8:44 pm

Sharing of information is not evolution. Its like sharing library books instead of writing new ones. Biologists are continuing to uncover ways that living things pass around what they know. This is not good for Darwinism, which requires new information to arise by chance.

Science Daily uses the analogy of fishing with rod and reel to illustrate what bacteria do to acquire information they need.

A new study from Indiana University has revealed a previously unknown role a protein plays in helping bacteria reel in DNA in their environment like a fisherman pulling up a catch from the ocean.

The discovery was made possible by a new imaging method invented at IU that let scientists see for the first time how bacteria use their long and mobile appendages called pili to bind to, or harpoon, DNA in the environment. The new study, reported Oct. 18 in the journal PLOS Genetics, focuses on how they reel their catch back in. [Emphasis added.]

Pili (singular, pilus) are tiny extensions from the cell membrane that grow out and then retract. Why should a bacterium invent a way to defeat antibiotics when it can fish for it? The paper indicates two issues for ID vs Darwinism: (1) information is shared, and (2) molecular motors do the work.

Almost all bacterial species use thin surface appendages called pili to interact with their environments. These structures are critical for the virulence of many pathogens and represent one major way that bacteria share DNA with one another, which contributes to the spread of antibiotic resistance. To carry out their function, pili dynamically extend and retract from the bacterial surface. Here, we show that retraction of pili in some systems is determined by the combined activity of two motor ATPase [i.e., ATP-spending] proteins.

This is a far cry from claims by Darwinians decades ago that the rise of antibiotic resistance represents Darwinian evolution in action before our eyes.

The promise of making your own household goods by 3-D printing them hasnt quite arrived, but in theory, you could make a complex object of any shape, like a car part or tool, on your 3-D printer if you had the code for it. A recent paper in PNAS suggests that something similar happens in yeast. In this case, a prokaryote shares information with a eukaryote. Carla and Paula Gonalves found a way that eukaryotic yeasts which lost the code for vitamin B1 can retrieve it from bacteria and make their own again.

Food is the only source of the essential vitamin B1 for humans, but many microorganisms such as yeast and bacteria can synthetize it themselves. Here we report on a group of yeasts that have lost part of the vitamin B1 biosynthetic pathway in the past but have managed to rebuild it by capturing multiple genes from bacteria through horizontal gene transfer (HGT). We show a mosaic pathway composed of yeast and bacterial genes working coordinately to accomplish the synthesis of an essential nutrient. This involved adaptation of the bacterial genes to the very different expression rules in their new environment using several different mechanisms. Our results endorse HGT as an important mechanism for evolutionary adaptation in eukaryotes.

The authors can call it evolutionary adaptation to please the censors, but its really information sharing. Nothing evolved. The yeast didnt re-invent the vitamin B1 synthesis pathway; they lost it (as Behe would say, they devolved), and so they borrowed genetic instructions from bacteria to get back to where they used to be. The authors very few instances of the words evolved and evolution in the paper seem superfluous to any serious consideration of causation or explanation.

Picture information-sharing tunnels at the nanometer scale. These would be way too small to see, so it would require indirect imaging techniques to observe them in action. A team of scientists possibly uncovered a novel mechanism in mammalian inter-cellular cytoplasmic transfer and communication between mammalian cells. Its just a preprint in bioRxiv, so the story will need further verification, but if observations confirm what the scientists think they are seeing, tunneling nanotubes and fine and often branching cell projections pass organellar cargo from cell to cell. In their experiments, healthy cells were found pumping material to malignant cells.

Discrete, rapid and highly localized transfer events, evidenced against a role for shed vesicles. Transfer coincided with rapid retraction of the cell-projections, suggesting a hydrodynamic mechanism. Increased hydrodynamic pressure in retracting cell-projections normally returns cytoplasm to the cell body. We hypothesize cell-projection pumping (CPP), where cytoplasm in retracting cell-projections partially equilibrates into adjacent recipient cells via micro-fusions that form temporary inter-cellular cytoplasmic continuities.

Cells can not only use protrusions to pump but also to poke neighboring malignant cells. In Nature, Kendall Powell discusses the growing realization among microbiologists that cells can evict, kill or cannibalize less-fit rivals. To do that, cells must have methods of sensing who is good and who is bad, and cooperating as a team. The burgeoning field of cell competition uses the Darwinian lingo of fitness and competition, but this really sounds more like a case of what Marcos Eberlin calls Foresight: the ability to foresee problems and have mechanisms in advance to deal with them.

The best-known case of genetic information sharing is, of course, sexual reproduction. Humans are all one species, Homo sapiens, so everyone is genetically compatible. But what about alleged human ancestors with other species names? Can they share genes?

One of the most astonishing developments in paleoanthropology in the last two decades was the discovery of Neanderthal DNA within us. As the myth of Neanderthals being other members of Homo began to crumble, first it was small bits of Neanderthal DNA, then more and larger segments. Next, Denisovan DNA was found mixed in with Neanderthal and living human genomes. Now, New Scientist reports, Long strand of DNA from Neanderthals found in people from Melanesia. Some paleoanthropologists are thinking that all three groups were genetically compatible with Homo erectus and other archaic humans.

Michael Marshall suggests that theres function, not just randomness, in these cases of genetic mixing:

The archaics have contributed to the success of humans that left Africa, says Eichler. Neanderthals and Denisovans lived in Europe and Asia for hundreds of thousands of years before modern humans emerged from Africa, so they would have evolved adaptations to the different climates, foods and diseases. These useful genes were kind of test-run in our precursors, says Eichler. Theyre basically borrowed.

Predictably, Marshall remains Darwinian in his thesis, but its not necessary to assume that the Africans invented their adaptations by chance mutations and natural selection. ID research could approach the same observations with Foresight in mind: humans have always had engineered mechanisms that could adapt to a wide variety of circumstances. If African meets European and they get twinkles in their eyes, why, theres a quick way to share their library books.

So, scientists continue to find ways that organisms share pre-existing genetic information. Old Darwinian paradigms continue to fall as observations reveal useful information passing through tunneling nanotubes, pili, and secretion systems from cell to cell. Organisms wouldnt borrow useless junk. If they are found reeling in DNA or passing it through secret passageways, it must be a good read.

Photo: Library shelves, bySusan YinviaUnsplash.

Visit link:
More Ways of Information Sharing Found in Living Things - Discovery Institute

Read More...

Is Protein Therapeutic Market Trapped Between Growth Expectations and Uncertainty? – Daily Market Headlines

November 15th, 2019 8:44 pm

AMA recently published a detailed study of over 180+ pages in its repository on Protein Therapeutic market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are Merck KGaA (Germany),Thermo Fisher Scientific Inc. (United States),Becton, Dickinson & Company (United States),Agilent Technologies, Inc. (United States),QIAGEN N.V. (Netherlands),Takara Bio Inc. (Japan) ,Lonza Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (United States),GenScript Biotech Corporation (China) ,Lucigen Corporation (United States),Synthetic Genomics Inc. (United States),Promega Corporation (United States),New England Biolabs, Inc. (United States) ,Sengenics (Singapore)

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/85549-global-protein-therapeutic-market

Protein Therapeutic refers to proteins which are engineered in the laboratory so it can be used in pharmaceutical use. These are an important class of drugs which serves patient in need of novel therapies. Protein Therapeutics treat a wide array of clinical indication which includes cancer, infectious diseases, genetic disorder and metabolic disorder.

Market Segmentation:by Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Hormonal Disorders, Genetic Disorders, Others), End User (Pharmaceutical and Biotechnology Companies, Healthcare service providers, Research Organizations and Academic Research Institutes, Other)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/85549-global-protein-therapeutic-market

Whats Trending in Market:Technological Advancements Such As Mass Spectrometry, Advances In Molecular Genetics, And Progress In Production Technologies

Growth Drivers:

Increase In Prevalence Of Chronic Diseases

Government Initiative to Improve The Healthcare Services

Rising Demand For High-Quality Recombinant Therapeutics

Rising Research Activities On Protein Therapeutics

Restraints:

High Costs Associated With Therapeutic Proteins

Binding Government Regulations For Protein Therapeutics

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/85549-global-protein-therapeutic-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Strategic Points Covered in Table of Content of Global Protein Therapeutic Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Protein Therapeutic market

Chapter 2: Exclusive Summary the basic information of the Protein Therapeutic Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Protein Therapeutic

Chapter 4: Presenting the Protein Therapeutic Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Protein Therapeutic market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=85549

Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@advancemarketanalytics.com

Ph: +1 (206) 317 1218

Continue reading here:
Is Protein Therapeutic Market Trapped Between Growth Expectations and Uncertainty? - Daily Market Headlines

Read More...

KWASU advocates increased agric production to meet global population by 2020 – NIGERIAN TRIBUNE

November 15th, 2019 8:44 pm

A professor of molecular genetics and plant breeding in the department of crop production, College of Agriculture, Kwara State University (KWASU), Olawale Aliyu, had said that agricultural production must increase by 80 per cent to meet world population of 7.7 billion to 10 billion by 2020.

Delivering sixth inaugural lecture of the university, titled, Decoding the secret of life: Plant, sex and sustainable food production, Professor Aliyu said that innovative breeding technologies for improving existing crops for better adaptation, among other measures, should be embarked upon to achieve the task ahead.

The KWASU don, who charged the federal government to give urgent priority to research by providing resources for functional laboratories, said that such labs should be equipped with modern technologies.

Theres the urgent need for the federal government to give priority to research by providing resources for functional laboratories, equipped with modern technologies and training of manpower that will carry out advanced research in agricultural production for sustainable food security.

The government should also strengthen the capacity of Nigerian scientists to embark on genetic engineering of our major food crops in addition to the conventional system being used.

ALSO READ:Changing outdated curriculum

The government should put in place monitoring mechanism to prevent the influx of GMO crops into the country because of its effect on the biodiversity of our plant and animal resources. Our national breeding programmes on cereals and grain legumes should consider integrating the use of apomixis technology for hybrid seed development because of its potential to revolutionize agriculture, he said.

Professor Aliyu, who said that advances in genetic research are moving at jet speed, added that there is an urgent need to review training curriculum in plant breeding and genetics for students in Nigerian universities to reflect current realities.

The KWASU don also said that cashew has the potential to transform the economy of Kwara state, adding that the sector should be properly organized and the industry is supported.

There is an urgent need for the Kwara state government to develop a 10-year strategic plan for the transformation of an agricultural commodity, especially cashew, where it has a competitive advantage. I am aware that the state government initiated a farmer-ownership cashew project that targeted 5,000 hectares per local government area with processing plants in each senatorial district in 2005, but this project was aborted before takeoff. The current administration can revisit this as part of the effort to lay a solid foundation for a sustainable economy of our dear state. The state government should partner with the federal government to stop the illegal shipment of nuts across porous borders to neighbouring countries, he said.

Read the original:
KWASU advocates increased agric production to meet global population by 2020 - NIGERIAN TRIBUNE

Read More...

Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment – BioSpace

November 15th, 2019 8:43 pm

The following is an opinion article written by Laura Towart, CEO and founder of My Personal Therapeutics, a London based digital health company offering advanced personalized cancer therapeutics. Their Personal Discovery Process uses fruit fly avatars to genetically mimic a patients cancer to identify drug combinations against the specific cancer. You can learn more about the company by reading this BioSpace article or going to their website.

The medical sector is getting carried away with a one size fits all approach to cancer treatment.

A cancer diagnosis simply means the patient has a condition that propagates abnormal cells within their body. This conditions underlying cause and characteristics will naturally differ between patients, but oncologists tend to prescribe a shockingly consistent course of treatment: anti-cancer medication and a course of chemotherapy. An estimated 1,735,350 Americans were diagnosed with cancer in 2018, but 1.7 million people cant all be the same.

Consumers have come to expect high levels of personalization from their smartphones, home designs, and online shopping experiences, and end up enjoying these things more as a result. They also deserve a personalized approach in cancer treatment that considers their unique genetic traits and the latest medical research this methodology stands a significantly increased chance of pushing back against the disease.

Personalized medicine tailors medical treatment to each patients unique characteristics

Factoring in conventional data points about the individual patient is just the start: their medical history, which country theyre from, and how physically active they are certainly constitute useful markers to guide treatment. But now its possible to go several layers beyond that and achieve a fuller picture by sampling the patients DNA, gaining a view into the genetic recipe that makes them who they are.

When scientists sequenced the complete human genome in 2003, it unlocked a new era of medical possibilities. There are approximately 3 billion pairs of chemical building blocks (called bases) in the human genome; the order in which they appear reveals the genetic information that each segment of DNA carries. In other words, medical researchers had developed a kind of Rosetta Stone for human genetic information. This forms the underpinning for personalized medicine today.

Medical professionals working in this arena can enhance their understanding of how someones unique molecular and genetic profile might leave them vulnerable to certain diseases or conditions, whether that information was already medically known or not. Where previous approaches to cancer treatment presented oncologists with a set of assumed best practices, personalized medicine gives them a figurative telescope to explore many possible treatments and determine one with an optimal outcome.

Fruit flies can be a powerful weapon for personalized medicine professionals

Medical researchers can use fruit flies to see the future. At the surface level, these kitchen pests have basically nothing to do with human biology, but they actually share up to 75 percent of the genes associated with human disease. Theyre furthermore one of the most genetically malleable organisms out there, capable of handling 15 mutations or more.

They present us with a valuable analog to see how a human body will metabolize and distribute a drug. A tumor generated in the fly gut can resemble a human colorectal tumor. As its inside the body (instead of on a cancer cell culture plate), it actually interacts with other organs in a long-range communication process. In other words, medical researchers like the ones at Mount Sinais Center for Personalised Cancer Therapeutics (CPCT) or at partner company My Personal Therapeutics can direct a genetically similar tumor to grow inside of a fruit fly, then experiment on it to see what kind of treatment works. Because fruit fly lifespans are very short, its easy to do this at a large scale and get meaningful results very quickly.

Personalized medicine will change the way we think about, identify, and manage cancer

Youve probably heard the term big data before in reference to business and internet technology. When the medical world collects highly precise data about individual patients at scale, it effectively lays the foundation for a comparative database that will make high-quality diagnoses quicker and more affordable in the future. In the long term, this will present doctors with trusted shortcuts for providing more accurate cancer treatment.

Imagine that personalized medicine has been the norm for 20 years and every physician has access to data that compares symptoms and treatments across all individuals. Doctors would only need to plug your vital statistics into a database and check them against your declared symptoms in order to see what worked for other people just like you. When I say just like you, I really mean it. This is the value of big data well eventually be able to segment out previous patients of all different demographics with deep specificity.

The future of cancer treatment is much like the future of medicine at large. Its going to depend on highly individualized approaches that harness all of a patients data, from their lifestyle to their genetic code. Genetic methodologies grant medical professionals access to a fuller picture of patient health than theyve ever had before. Its time to start using them on an individual basis in order to ensure high-quality outcomes for cancer patients.

You dont need to be a medical expert to know one size doesnt fit all.

Go here to see the original:
Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment - BioSpace

Read More...

A Revolution in the Creation of Scientific Workplaces – Scientific American

November 15th, 2019 8:43 pm

In todays hypercompetitive research environment, successful organizations know strategic workplace design is no longer a luxury. Historically, providing a private office and a large wet lab were enough to attract great talent and achieve expected results.

However, todays researchers are challenging the status quo as they seek creative ways to perform their work. These researchers are looking for workspaces that enable new levels of collaboration, creativity, flexibility and well-being. Convergent scientific workplace design is based on the widely recognized convergence research model that has been proven to break down traditional barriers of scientific discovery and pave the way toward improved recruitment, retention, productivity and innovation.

WHAT IS CONVERGENCE RESEARCH?

Scientific research is undergoing a transformational change. Highly specialized gene therapies now cure once incurable cancers. Personalized medicine and big data help doctors treat and prevent diseases better than ever before. The ever-advancing technologies behind these breakthroughs are driving a new paradigm of cutting-edge, integrated research across multiple fields and industries that have been historically distinct disciplines. Many have defined this shift as the convergence revolutionone that shares methods and ideas from chemists, mathematicians, economists, computer scientists, biologists, physicists, engineers and more to improve the lives of millionsif not billionsof people.

Many initiatives are underway to expand awareness and encourage more scientists to adopt the convergence model of research. The National Science Foundation (NSF) has identified convergence research as one of its 10 Big Ideas for the agency and is creating a solicitation process to encourage convergence in a subset of its research and center awards. The National Academies Government-University-Industry Research Roundtable and the National Academy of Sciences have held formal workshops on the topic.

WHY IS WORKPLACE DESIGN IMPORTANT?

In this convergence research model, the scientific workplace environment is more important. With so many disciplines sharing the same spaceall with different needs and ways of workingand more remote team members needing means to collaborate, it is important for institutions to understand the role facility design can play in its success or failure. When we talk about optimizing the workplace environment, we are ultimately talking about the researchers within. They are the factors that influence performance, innovation and retentionall of which are measures of success for a research institution.

The cost of unhappy researchers can be devastating. In a paper titled Innovation spaces: Workspace planning and innovation in U.S. university research centers, researchers Umut Toker and Denis Gray cite that over a period of 10 years, operating and maintenance costs of an organization remain around 8 percent, whereas human costs remain around 85-90 percent. It is much more advantageous for institutions to focus on long-term productivity, increased collaboration, and reduction of turnover to reduce cost rather than focusing on the short-term, operational and maintenance of the facility itself.

Sometimes it is seemingly more difficult to demonstrate how workplace planning can influence innovation in an organization. Toker and Grays study proved this correlation through data analysis that there is a significant relationship between workspace planning, consultations and innovation process outcomes, citing that university research centers featuring overall high configurational accessibility, shorter walking distances and intact territories exhibit higher face-to-face consultation rates, consultation network connectivity, and subjective/objective innovation process outcomes.

WHAT DESIGN STRATEGIES CAN IMPROVE RESEARCH OUTCOMES?

When renovating or creating a new research work environment, there are three important design strategies to consider that can ultimately affect research outcomes.

Collaboration

Far too often, scientists are separated from each other in formally arranged spaces, reflecting linear processes and static functionality, and status is reflected by size of internal real estate and the allocation of enclosed offices. The convergence research environment embraces new methodologies of working where multidisciplinary teams can come together away from their departmental homes. Through design, we can encourage informal social interactions and foster intentional collisions of people with diverse backgrounds and skill sets to catalyze innovation.

In order to foster social ties, workplaces should make it easier for people to interact and provide places where people are comfortable talking about things other than work. One tactic is to create social spaces at intersections where people are likely to bump into acquaintances with whom they may not regularly work. To enhance the impact of central social spaces, these informal collaboration areas should be highly visible, located along central circulation paths and within reasonable walking distances of key collaborators. In addition, these spaces should have amenities such as coffee, snacks, seating and comfortable standing gathering areas.

A study at the University of Michigan supports co-locating team members, finding that researchers who occupy the same building are 33 percent more likely to form new collaborations than researchers who occupy different buildings, and scientists who occupy the same floor are 57 percent more likely to form new collaborations than investigators who occupy different buildings.

Example: Johns Hopkins University Applied Physics Laboratory, Building 201, Laurel, MD

Johns Hopkins University Applied Physics Laboratory Building 201 is an interdisciplinary research facility that will provide flexible laboratory and office space in a highly collaborative, open workplace environment. The laboratories are organized in a shared facility plan, which features glass enclosures that promote more interaction. They are designed around a four-story daylit atrium in conjunction with generous, unassigned collaborative spaces offering researchers many options for focused, informal and group work activities. Cafs are on every floor, which promote greater interactions between researchers from different departments. When complete, there will be over 50 different collaboration environments and over 20 different laboratory environments suited to fit researchers needs.

Flexibility

The performance of researchers is optimized when they feel they have some control over the physical conditions they experience there. Permanent fixtures and traditional laboratory layouts were designed for the slower-moving research of the past. However, researchers today are more mobile, more agile and desire a workplace that can be quickly and easily optimized for their needs. Flexibility within laboratories includes a multitude of integrated design approaches, including flexible engineering systems, modularity of furniture and casework, and accessibility. Key to accommodating flexibility is designing spaces that can easily transform when new processes are realized or new breakthroughs are discovered.

There should be a fluid mix of wet and dry spaces in a convergence research laboratory. This level of flexibility is beneficial because researchers in a convergence model are just as likely to be doing wet bench work as they are to be doing prototypes, physical and virtual simulations, data informatics and data analysis. Having the wet bench in close proximity to dry labs (and write-up areas) allows researchers to move quickly from task to task, without having to leave their floor or building.

Flexibility is the physical expression of convergence research. If we expect researchers to think broadly outside of their particular domains of expertise, we need to provide them spaces to interact and work alongside a wide-ranging team from traditional wet bench scientists to anthropologists.

A universal bench layout is also advised to increase flexibility. Using a best practice in the health care field, an overhead service boom can support the flexibility of a bench layout, which serves power, data and lab gases. Task lighting can also move with the furniture to ensure a consistently high-quality visual experience regardless of physical location.

Example: CJ Blossom Park, Suwon, South Korea

The 1.2 million sf building consolidates CJ Corporations previously disparate pharmaceutical, biotechnology, and food products businesses into a single location, enabling it to create industry-defining product strategies and increase its global competitiveness. The design team tested and explored a multitude of bench layouts through the design phase A universal bench design changes the traditional 6 wide x 2.5 deep bench to 5 x 2.5 so it is non-directional and can be configured in parallel or perpendicular direction. These are used throughout the building for both instrumentation and desk activities and provides greater flexibility and encourages more open teaming spaces.

The universal benches are all on wheels, which enable users to configure benches in several different wayslinear, T shaped, U shaped, or L shapedbased on team, project and process. The universal bench can be used for both instrumentation and desk activities. This allows even greater flexibility to scale up or down instrumentation or headcount for a multitude of changing environments such as contractors or summer interns. This also eliminates the need of write-up space in the lab and encourages more open teaming spaces.

Wellness

Lastlyand possibly most importantlyis the focus on researcher wellness. There is an incredible body of work that proves the correlation between the design of the workplace and the quality of work done by the people in it. Gone are the days of researchers tolerating a workplace in the basement. Despite strict environmental requirements in many spaces, researchers nevertheless are expecting workplaces that deliver on their wellness needs. Research space needs to focus on human health through strategies such as natural light, soft seating and acoustics. Researcher comfort and satisfaction are crucial, as it can greatly influence recruiting and retention as discussed above.

Ample access to daylight has proven time and again its benefits in the workplace. In a laboratory setting, this may prove more difficult due to challenges like photosensitive materials handling and glare concerns. However, there are design strategies that can improve daylight access. Consider orienting seating perpendicular to exterior windows. Provide shading devices, particularly on south and west facing windows. Place light sensitive equipment in the center of the floorplate away from the exterior. Consider borrowing daylight into labs from write-up areas and offices.

Noise control has also proven critical to workplace wellness. This factor is often overlooked or is taken out of the design as a cost-saving measure, but it is highly important and should be seriously considered when designing a laboratory environment. Noise reduction strategies can include creating equipment rooms for loud, noisy equipment like minus 80 degree F freezers. Break down large, open labs by zoning into smaller spaces through glass walls, demountable walls, or floor-mounted equipment (like fume hoods). Finally, consider acoustics in ceiling and floor selection.

Example: Novartis-Penn Center for Advanced Cellular Therapies (CACT), Philadelphia

Located on Penn Medicines campus in Philadelphia amidst both clinical care and laboratory facilities, the 30,000 sf Center for Advanced Cellular Therapies (CACT) brings together Penn Medicines intellectual resources combined with pharmaceutical industry leader Novartis with the mutual goal of expediting the development of novel gene therapies for complex diseases of all kinds. To take advantage of the natural light and views, the processing cells are located on the perimeter using a double-wall construction design that provides the necessary isolation of the controlled environment. Additionally, to shield the material from ultraviolet rays, the design team installed polarized film on the windows for some of the most sensitive rooms in the facility so that, with a flick of a switch, the polarization is activated.

Convergence research is the future of science. It is not easy to bring together the strengths of many disciplines; however, it is necessary to help solve the incredibly complex challenges of today and tomorrow. Convergent scientific workplaces can be designed to promote collaboration, flexibility and wellnessall of which can lead to better research outcomes.

For more information on this topic, please see this white paper.

View original post here:
A Revolution in the Creation of Scientific Workplaces - Scientific American

Read More...

Personalized Medicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry…

November 15th, 2019 8:43 pm

The Global Personalized Medicine Market (2019 2026) research offers a basic overview of the industry including definitions, applications, classifications, and market chain structure. Moreover, in the global Personalized Medicine Market report, the key product categories of the market are included. The report comparably demonstrates supportive data related to the dominant players in the market, for instance, product offerings, segmentation, revenue, and business synopsis. The global Personalized Medicine Market is as well analyzed on the basis of numerous regions. The firstly the report describes the market overview, cost structure, upstream, and technology. The second part describes the global Personalized Medicine market by key players, by application and type.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/personalized-medicine-market-ric/773699/request-sample

Competitive Analysis

The global Personalized Medicine market report wraps scope and product overview to define the key terms and offers comprehensive information about market dynamics to the readers. This is trailed by the regional outlook and segmental analysis. The report also consists of the facts and key values of the global Personalized Medicine market in terms of sales and volume, revenue and growth rate.

One of the important factors in the global Personalized Medicine market report is competitive analysis. The report covers all the key factors, such as product innovation, market strategies of the key players, market share, revenue generation, latest research and development, and market expert views.

The followingTopmanufacturersare assessed in this report:

Abbott LaboratoriesAgilent TechnologiesAmgenAstellas PharmaAstrazenecaBayer AGCelgene CorporationGlaxosmithkline PlcIlluminaJohnson & JohnsonLaboratory CorporationMerckNovartis AGRoche Holding AGSiemens AGTakeda Pharmaceutical Company Limited

Personalized Medicine Market Segmentation

For the better grasp insight of the market, this report has provided a detailed analysis of drivers restraints, and trends that dominate the present market scenario and also the future status of the global Personalized Medicine market during the projected period of 2018-2026.

Market Analysis by Product Type

Personalized Medicine DiagnosticsPersonalized Medical CarePersonalized Medicine TherapeuticsPersonalized Nutrition and Wellness

Market Analysis by End-User Application

OncologyCentral Nervous System (CNS)ImmunologyRespiratoryOther Applications

While classifying these segments, the expert team of analysts has listed the relative contribution of each segment for the growth of the global Personalized Medicine market. Detail information of segments is required to recognize the key trends influencing the global market for the Personalized Medicine.

Each segment of the market provides a piece of in-depth information on the qualitative and quantitative aspects of the market. While giving a brief idea about the revenue opportunities for all the segments, this report has also provided the value of absolute dollar opportunity for all the segments over the predicted period of 2018 2026.

Regional Analysis

The significant regions covered in the reports of the global Personalized Medicine market are North America, Europe, the Asia Pacific, South America, and the Middle East and Africa. The market information not only provides the market data of the five geographies as a whole, but it also provides you qualitative as well we qualitative information on country level bifurcation. Adding to that, economic, technological, cultural and social aspects along with the regulatory barriers are entirely analyzed to understand the thorough market scenario across different geographies.

The key highlight of the Research:

Key Questions Answered:

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-020-67320403

Email help@researchindustry.us

Original post:
Personalized Medicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry...

Read More...

UC Davis leads in innovative gene editing research with NIH grants – The Aggie

November 15th, 2019 8:43 pm

Researchers strive to address societal health issues through gene editing

In October, three researchers at UC Davis were awarded a $1.5 million grant to fund their project which attempts to demonstrate the effectiveness of gene editing through use of CRISPR, a powerful technology that allows alteration of DNA sequences to change gene function.

This kind of design can help enhance personalized medicine, said R. Holland Cheng, a professor of molecular and cellular biology in the College of Biological Sciences. Specific patients with specific illnesses can be treated in specific ways.

Cheng, along with Kit Lam, a distinguished professor and chair of the Department of Biochemistry and Molecular Medicine in the School of Medicine, and David Segal, a professor in the Department of Biochemistry and Molecular Medicine, were awarded this highly competitive and sought-after grant from the National Institute of Health (NIH).

UC Davis is part of the NIHs Somatic Cell Genome Editing (SCGE) consortium which has awarded grants to 45 other research institutes across the nation so they can begin groundbreaking work on gene editing. Through this consortium, the NIH hopes to find an efficient and safe way to conduct gene editing. Research programs are investigating the best delivery mechanism as well as the most dynamic gene editing tool.

The major problem with gene editing currently is the inability of cells to be edited within a living organism. It has become fairly easy and efficient to edit genes in a cell culture outside of the body but extremely difficult to do the same processes inside the body. Cheng, Lam and Segal are focused on changing this.

The question is how to do it inside of an animal and eventually a human, Lam said.

They are answering this question by utilizing Chengs work in engineering a non-toxic nanoparticle that they hope can transport the gene editing tool CRISPR into the cells of a living organism. Cheng has been able to create a Hepatitis E viral nanoparticle (HEVNP) that when manipulated could be a delivery system for CRISPR. They plan to take this nanoparticle and encase CRISPR inside of it, producing a mechanism for delivery of CRISPR.

The Hepatitis E nanoparticle has the capacity to be a highly efficient way to deliver gene editing to cells in the body due to its unique nature. HEVNP is resistant to the gastric acid environment of the intestines and stomach, enabling it to survive once its entered the body. Given its resistant abilities, HEVNP can be taken orally, making it a useful form of medicine. If able to successfully get HEVNP to the target cells in the body and deploy CRISPR, gene editing abilities could drastically change.

The addition of a cell-type specific targeting ligand to the HEVNP would code the nanoparticle to deliver CRISPR to a specific cell. The abilities of this method to be precise and safe will determine its success.

With five years of funding from the NIH, these three researchers are eager to begin work on this project and see the strides that can be made in gene editing. They have impressive goals for this research, as it has the capacity to reshape medicine.

This will redefine precision medicine as currently there is broad medicine that can cause side effects to people and not be effective, yet by making it specialized it is becoming more precise and effective, Cheng said.

As more effective and safe tools to cure illnesses are being tested and created, the benefits to society could be expansive. With so much potential to help improve the health of society, the NIH is dedicated to coming to new solutions at a quick rate. All programs that received grants will be required to share and utilize the research occurring at other funded programs. The NIH is hoping to eliminate the private nature of research through enforcing the sharing of ideas, as scientists are often constrained by the institutions they work for. It is their hope that by having communication between the programs, positive results will arise faster.

I think this is great because scientists inherently want to work with each other but have real world concerns especially with money, Segal said.

The research results, when groundbreaking, can provide incredible monetary gains and credibility to the institutions that made the discovery. Ultimately, scientists collaborating with one another will serve society as people are able to benefit earlier from this innovative research.

We want the public to know that we are working in their best interest, Segal said.

The NIH grant is competitive and still the third research program to join the consortium at UC Davis. Innovation has never been more prevalent than in this field at UC Davis. With three different programs researching gene editing, UC Davis stands out as a hotspot for this field of research.

Written by: Alma Meckler-Pacheco science@theaggie.org

Go here to see the original:
UC Davis leads in innovative gene editing research with NIH grants - The Aggie

Read More...

Lifebit and Medley Genomics Partner to Deliver Streamlined Solution Supporting New Diagnostic and Therapeutic Discoveries – BioSpace

November 15th, 2019 8:43 pm

Researchers can now tap new disease discoveries using Medley Genomics HotNet2 at enterprise scale, over any system, across distributed data with Lifebit CloudOS

LONDON, UK - Nov 14, 2019 - Lifebit Biotech, a leading innovator in bioinformatics and cognitive software solutions, and Medley Genomics, a company focused on using advanced data analytics to support better diagnosis and treatment of complex diseases, announced today their partnership agreement. The Lifebit-Medley partnership aims at removing the barriers impeding progress in precision medicine where advanced biomedical analysis tools, like HotNet2, must be deployed over distributed and complex data to arrive at breakthrough insights.

Lifebit CEO, Dr Maria Chatzou Dunford, said, We are thrilled to announce our partnership with Medley Genomics, which allows us to bring advanced tools to the biomedical research community, advancing knowledge by powering the investigation of new diagnostic and therapeutic opportunities. Any company or researcher can now discover disease driver genes and novel pathways by utilising the high performance HotNet2 at enterprise scale and over distributed cohorts of patient data without needing to move the data.

Developed by Medley co-founder Dr Ben Raphael, HotNet2 assesses the complex heterogeneous genomic landscape across patient cohorts, including the long tail of disease relevant genes, by building significantly mutated gene subnetworks based on mutational frequencies and known interaction networks. Because HotNet2 comes with many dependencies, installation was complex without Lifebit CloudOS. To increase the power of analysis, experimental setups need to include as many samples as possible. Unless users have endless resources to spend on sequencing and data generation, they would need to combine disconnected data from various public and private sources, presenting a major obstacle to progress.

With Lifebit CloudOS, HotNet2 now runs over distributed data using federated capabilities, providing immediate access to infinite compute resources, said Dr Patrice Milos, Medley Genomics CEO. Increasingly our customers are applying HotNet2 to define subgroups within their patient disease cohorts and to reveal novel biological pathways. Our partnership with Lifebit enables us to reach countless more researchers across our shared communities helping them to simplify their work processes and ultimately bring important discoveries to patients faster.

By deploying HotNet2 with Lifebit CloudOS, analyses are seamlessly executed and distributed data is united through federated analysis - data is never transferred and security is assured. This is critical as analyses can run at sample-level within the users cohort or across different patient cohorts, without compromising the data by moving them outside their secure environment. Detailed reports can be generated at scale, including visualisations for each run, and instantly shared for true collaboration across teams. The HotNet2 solution is available to anyone via the Lifebit CloudOS Marketplace.

View pan-cancer HotNet analysis here.Try cloud-native HotNet2 here.

ABOUT LIFEBITLeading life sciences organisations are accelerating their research and discoveries with Lifebit. Lifebit CloudOS is the federated, integrated solution for fully FAIR omics and biomedical analysis, allowing anyone to streamline and scale analyses faster, cheaper, and securely in their own data environments. Lifebit AI-Engine has deep-learned the biology behind drug response and is helping pharmaceutical companies repurpose drugs, validate targets and optimise vaccines by reasoning about omics data like humans would. Headquartered in London, UK, Lifebits ecosystem of employees, partners, and customers spans 15 countries. Visit lifebit.aiLifebit press contact: pr@lifebit.ai

ABOUT MEDLEY GENOMICSMedley Genomics Inc., based in Providence, Rhode Island, US, provides cutting edge algorithms and software to deliver on the promise of individualization of therapy. The companys approaches provide deep insight into the heterogeneity of disease as well as defining unique disease mechanisms across disease cohorts. Applied first in oncology, these insights are necessary for optimizing targeted and combination therapies, personalized cancer vaccines and immunotherapies to effectively treat the total disease burden and offer hope of lasting cures for patients. Visit Medleygenomics.comMedley press contact: info@medleygenomics.com

See the article here:
Lifebit and Medley Genomics Partner to Deliver Streamlined Solution Supporting New Diagnostic and Therapeutic Discoveries - BioSpace

Read More...

Page 810«..1020..809810811812..820830..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick